Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00247689 · ClinicalTrials.gov registry record
Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics
A clinical trial, sponsored by National Institute on Drug Abuse (NIDA).
- Terminated
- Registry status
- 31
- Enrollment target
NCT00247689 is a clinical trial that was terminated before completion, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 31 participants.
The verdict
NCT00247689 was terminated before completion, sponsored by National Institute on Drug Abuse (NIDA).
- TERMINATED
- Registry status
- 31 participants
- Enrollment target
Study Summary
Background: * Research has shown that several human genes have been associated with vulnerability to substance abuse and dependence. However, little is known about how people with these genetic tendencies react to drugs in controlled settings. * Methylphenidate, also known as Ritalin, is commonly prescribed for a number of conditions, including attention deficit disorder. Because methylphenidate is widely used in studies of brain chemistry and behavior and has relatively low risks associated with it use, researchers are interested in seeing how it affects the thinking processes of people with apparent genetic vulnerability to drug abuse. Objectives: \- To evaluate whether individuals with apparent genetic vulnerability to drug abuse react differently to methylphenidate than people who do not have this vulnerability. Eligibility: \- Individuals at least 18 years of age or older who have participated in the NIDA protocol Allelic Linkage in Substance Abuse. Design: * Participants will be asked to avoid using a number of over-the-counter medications, including antihistamines, cough medicines, and nasal decongestants, for 24 hours before the study day. Participants will also be asked to avoid consuming caffeinated beverages, nicotine or tobacco products, or alcohol on the morning of the day of the study, and will provide a urine sample at the start of the study to be tested for chemicals that may interfere with the study. * Because of the nature of the study drug, participants will not be allowed to drive to the clinical center on the day of the study. (Return transportation will be arranged.) * At the start of the study, participants will take two tablets (each 1 hour apart), and will not be told whether the tablets are the study drug or a placebo. * Participants will give regular answers to questions about mood and thinking processes on a computer for approximately 5 hours. Blood samples will be taken during this part of the study.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2004-12-22 |
| Est. Completion | 2015-02-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00247689
The ClinicalTrials.gov registry entry for NCT00247689 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00247689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00247689 about?
NCT00247689 is a clinical study titled "Methylphenidate Studies for Drug Abuse Vulnerability Molecular Genentics". Background: * Research has shown that several human genes have been associated with vulnerability to substance abuse and dependence. However, little is known about how people with these genetic tendencies react to drugs in controlled settings. * Methylphenidate, also known as Ritalin, is commonly p...
What is the current status of trial NCT00247689?
This trial is currently terminated. The enrollment target is 31 participants. The study started on 2004-12-22. Estimated completion is 2015-02-27.
Who is sponsoring clinical trial NCT00247689?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.